Clinical Trial Update: Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of belantamab mafodotin in relapsed/refractory plasmablastic lymphoma and ALK-positive large B-cell lymphoma was terminated, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Large B-cell Lymphoma
• Plasmablastic Lymphoma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Sponsor: Jacob Soumerai, MD | Conditions: Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2026-03-13